2020
Molecular “omic” signatures in systemic sclerosis
Mehta BK, Department of Molecular and Systems Biology G, Espinoza M, Hinchcliff M, Whitfield M, Department of Rheumatology A, Department of Biomedical Data Science D. Molecular “omic” signatures in systemic sclerosis. European Journal Of Rheumatology 2020, 7: 173-180. PMID: 33164732, PMCID: PMC7647683, DOI: 10.5152/eurjrheum.2020.19192.Peer-Reviewed Original ResearchDeregulated molecular pathwaysEpigenomic dataExtracellular matrix abnormalitiesMolecular pathwaysTiming of activationDisease phenotypeObserved clinical heterogeneityOmicsSSc researchMatrix abnormalitiesTranscriptomicsUnique insightsPhenotypePathwayPrecision medicineImportant stepActivationClinical heterogeneityIdentification
2016
Molecular Stratification by Gene Expression as a Paradigm for Precision Medicine in Systemic Sclerosis
Hinchcliff M, Whitfield M. Molecular Stratification by Gene Expression as a Paradigm for Precision Medicine in Systemic Sclerosis. 2016, 657-670. DOI: 10.1007/978-3-319-31407-5_49.Peer-Reviewed Original ResearchSystemic sclerosisPatient subsetsProgressive interstitial lung diseaseDiffuse cutaneous systemic sclerosisAppropriate patient subsetsScleroderma renal crisisCutaneous systemic sclerosisInvestigator-initiated trialPulmonary arterial hypertensionSubset of patientsDifferent patient subsetsInterstitial lung diseaseDifferent pathophysiological processesMolecular pathwaysPrecision medicineGene expression subsetsT lymphocyte activationUninvolved skin samplesInflammatory subsetRenal crisisSSc complicationsArterial hypertensionMycophenolate mofetilClinical improvementOrgan involvement